[1] RAGHU G, COLLARD HR, EGAN JJ, et al.An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-804. [2] MARTINEZ FJ, COLLARD HR, PARDO A, et al.Idiopathic pulmonary fibrosis[J]. Nat Rev Dis Primers, 2017, 3(1): 70-74. [3] FU Y, YANG CY, WEI DX, et al.Effects and mechanism of Yunnan minority medicine Qilongtian on inhibiting pulmonary angiogenesis induced by hypoxia[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2014, 29(11): 3602-3604. [4] CHEN B, YANG CY, ZENG KX, et al.Effects of Dian sanguis draconis on IL-4 and IFN-γ serum level in pulmonary fibrosis rats by staged intervention[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2020 , 35(7): 3611-3613. [5] CHEN B, YANG CY, WANG XL, et al.Effects of Dian sanguis draconis on FIZZ1 level in pulmonary fibrosis rats by staged intervention[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2020, 35(6): 3071-3074. [6] LENG P.Based on the image thinking of“Tianlongjie”regimen for IPF different periods and treatment of clinical research[D]. Kunming: Yunnan University of Traditional Chinses Medicine, 2017. [7] HUANG BC.Based on the image thinking of“Tianlongjie”regimen for IPF different periods and treatment of comprehensive efficacy observation[D]. Kunming: Yunnan University of Traditional Chinses Medicine, 2018. [8] LIU Z, ZAHNG XM, QIN HH, et al.Influence of feixian formula extract on adhesion and migration of microvascular endothelial cell in pulmonary fibrosis rat model[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2015, 30(11): 4042-4044. [9] XU SY, BIAN RL, CHEN X.Methodology of Pharmacological Experiment(药理实验方法学)[M]. Third Edition, Beijing: People’s Medical Publishing House, 2002: 1030-1033. [10] SCHISSEL SL, LAYNE MD.Telomerase, myofibroblasts, and pulmonary fibrosis[J]. Am J Respir Cell Mol Biol, 2006, 34(5): 520-522. [11] HU Q, ZHANG CX, KE SR.The mechanism of autophagy regulating epithelial-mesenchymal transition in pulmonary fibrosis[J]. Journal of Applied Medicine(实用医学杂志), 2022, 38(1): 38-44. [12] QIAN JD, SUN RQ, HUAN CJ.Correlation between the levels of immunoglobulin A, MeCP2 and inflammatory factors and pulmonary function in patients with idiopathic pulmonary fibrosis[J]. Health Research(健康研究), 2021, 41(5): 542-545. [13] WU JM, ZHANG W, ZHANG X, et al.Immunomodulatory effects of exosomes from different resources on idiopathic pulmonary fibrosis[J]. Journal of New Medicine(新医学), 2022, 53(5): 336-339. [14] HU XL, CHEN SN, LU J.Research progress in prevention and treatment of Idiopathic pulmonary fibrosis with traditional Chinese medicine targeting TGF-β1/Smads signal pathway[J]. Shanxi Traditional Chinese medicine(山西中医) , 2023, 29(2): 65-67. [15] EPSTEIN SG, BROOK E, BARDENSTEIN-WALD B, et al.TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling[J]. Respir Res, 2020, 21(1): 56. [16] SU J.Changes and clinical significance of serum IGF-Ⅰ, VEGF and TGF-β1 levels in patients with combined pulmonary fibrosis and Emphysema[J]. Liaoning Medical Journal(辽宁医学杂志) , 2021, 35(5): 33-36. [17] HU Q, ZHANG CX, KE SR.Mechanism of autophagy regulating epithelial mesenchymal transformation in pulmonary fibrosis[J]. Journal of Applied Medicine(实用医学杂志), 2022, 38(1): 38-44. [18] LIAO MX, PAN RQ, AI CJ, et al.The relationship between serum KL-6, TGF-β and CXCL13 levels and the severity of pulmonary fibrosis and the value of combined prediction[J]. Journal of Medical Graduate Students(医学研究生学报), 2021, 34(1): 62-67. |